Cataracts, a common eye condition characterized by clouding of the lens, often lead to blurred vision and, if left untreated, ...
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...
She learned that she would have to try, and "fail," on two other drugs before Medicare would cover the new one.
Children who develop multiple sclerosis appear to fare better if they were exposed to safe amounts of summer sunshine as ...
Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...
Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...
Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...
Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results